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Abstract 
Glutathione metabolism was studied in rat liver during diethylnitrosamine (DEN) carcinogenesis. Some studies were also 
made in foetal rat liver. Endogenous GSH and non-protein thiols concentrations are increased in DEN-treated rats when 
compared to non-treated rats but no differences were found in cysteine, total thiols and protein thiols concentration. In foetal 
liver GSH concentration is only 35% of that in DEN-treated rat liver. The activities of several enzymes involved in 
glutathione metabolism are changed in DEN-treated rats. y-Glutamyl transferase activity and cysteine formation from GSH 
by liver homogenates is increased sevenfold, y-Glutamylcysteine synthetase activity, initial rate of [35S]cysteine incorpora- 
tion in y-glutamylcysteine and initial rate of GSH formation from [35S]cysteine are increased two-fold. Cytosolic GSH 
S-transferase activity is increased twofold in DEN-treated rats and so GSH S-conjugates concentration is probably also 
increased. In foetal rat liver y-glutamyl transferase activity is about the same but y-glutamylcysteine synthetase activity is 
only 10% of that in DEN-treated rat liver. The increased GSH concentration i DEN-treated rat liver is probably due to the 
simultaneous increase in the activities of y-glutamyl transferase and y-glutamylcysteine synthetase. Blood plasma total 
glutathione is increased 1.4 times in DEN-treated rats, but no differences are found in GSH hepatic arteriovenous gradient. 
This associated with the increased y-glutamyl transferase activity suggests that sinusoidal GSH effiux is increased in 
DEN-treated rats. 
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1. Introduction 
Glutathione the major non-protein thiol in mam- 
malian cells, is involved in many cellular functions 
including aminoacid transport [1], thiol-disulfide bal- 
ance [2,3], protection against oxidative stress [4] and 
detoxification of xenobiotics [5]. GSH has been sug- 
gested as a potential regulator of protein synthesis [6], 
DNA synthesis and cell proliferation [7]. Also high 
levels of GSH and of GSH related enzymes have 
been correlated with increased resistance to antineo- 
plastic drugs and ionising radiation [8,9] and with 
mitogenic stimulation [10]. 
In hepatomous liver of rats treated with the car- 
cinogen diethylnitrosamine, changes in GSH 
metabolism are observed namely a decreased sele- 
nium-dependent GSH peroxidase activity and an in- 
creased GSSG reductase activity [11] and an increase 
of GSH and non-protein thiols endogenous concentra- 
tion [12]. This increase of GSH endogenous concen- 
tration was also observed in hyperplasic nodules [ 13- 
16]. Hanigan and Pitot [17] suggested that this in- 
crease in GSH concentration during hepatocarcino- 
genesis is due to an induction of y-glutamyl trans- 
ferase activity. This increase of y-glutamyl trans- 
ferase activity in hepatocarcinogenesis could be re- 
sponsible for blood plasma GSH hydrolysis and/or 
formation of y-glutamylpeptides (mainly y-gluta- 
mylcysteine) that after transport into hepatocytes 
would allow them to obtain the aminoacids necessary 
for intracellular GSH synthesis and the subsequent 
use of GSH for conjugation. However regulation of 
GSH concentration i  liver is not only dependent on 
y-glutamyl transferase activity, for in foetal rat liver 
and in Novikoff hepatoma there is a low GSH con- 
centration although y-glutamyl transferase activity is 
markedly increased [18]. According to Ahluwalia and 
Farber [15] the increased GSH concentration found in 
early hyperplastic nodules could be due at least in 
part to an increased GSH synthesis. Induction of 
GSH deficiency in tumours have been postulated as 
being potentially useful in cancer therapy [19] and so 
it seems important to understand the factors regulat- 
ing GSH metabolism in hepatocarcinogenesis. 
In this work a detailed investigation of GSH 
metabolism in hepatomous liver of rats treated with 
DEN was made. This study included measurement of 
GSH and cysteine concentration, and determinations 
of GSH biosynthesis and degradation, GSH sinu- 
soidal efflux, cysteine uptake, GSH S-transferase and 
GSH peroxidase activities. 
2. Materials and methods 
2.1. Materials 
GSH, ATP, NADPH, 5,5'-dithiobis(2-nitrobenzoic 
acid) were from Boehringer Mannheim. L-Cysteine, 
glycine, cysteinylglycine, y-glutamylcysteine, GSSG 
reductase, a-aminobutyrate, glycylglycine, L-y- 
glutamyl-4-nitroanilide, 1-chloro-2,4-dinitrobenzene, 
diethylnitrosamine and bovine serum albumine were 
from Sigma Chemical Co. (St. Louis, MO, USA). 
Cumene hydroperoxide, hydrogen peroxide and L- 
glutamic acid were from Merck, Darmstadt. [35S]cy- 
steine (119 mCi/mmol; 4.4 GBq/mol) was obtained 
from Amersham. GSH peroxidase was the lyophilised 
soluble fraction of rat liver (see Section 2.5). 
2.2. Animals and treatments 
Male Wistar rats from Gulbenkian Foundation An- 
imal House were used. Rat foetus were obtained from 
pregnant female rats three days before birth (18 days 
gestation). Rats were fed ad libitum with a diet from 
Biosure (Barcelona, Spain) and were subject o a 12 h 
light/12 h dark cycle. Induction of liver tumours was 
produced by DEN (50 rag/l) given ad libitum in 
drinking to rats about 3 months old as described in 
Pinto and Bartley [11] except that rats were killed 
after 5 months treatment. 
2.3. Tissue preparation 
Rats were killed between 09:00 and 10:00 h by 
decapitation, bled and the liver quickly removed. For 
GSH, non-protein thiols and cysteine determinations, 
portions of the liver were immediately placed on 
liquid nitrogen and pulverised in a percussion mortar 
chilled with liquid nitrogen. For the non-protein thiol 
determinations, 0.2 g of powdered liver were added 
to a mixture of 1.0 ml of 0.154 M KC1 and 0.5 ml of 
10% (w/v) HPO 3. For GSH determinations, a 25% 
(w/v) homogenate in 3% (w/v) HPO 3 was made. 
Both suspensions were centrifuged at 30 000 × g for 
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20 min. The supernatant was collected for subsequent 
assays. For cysteine determinations [20], a 25% (w/v)  
homogenate in 5% (w/v)  perchloric acid was made. 
The homogenate was centrifuged at 2800 X g for 60 
min at 4°C. 
Other portions of liver were washed in 0.154 M 
KC1. For total thiols determinations liver was ho- 
mogenised in 39 vol of 0.154 M KC1 [21]. For 
y-glutamyl transferase activity determinations a 20% 
(w/v)  homogenate in 0.154 M KC1 was made. For 
cysteine formation from GSH experiments a 10% 
(w/v)  homogenate in 0.05 M potassium phosphate 
buffer (pH 7.4) was made. 
For the determinations of y-glutamylcysteine syn- 
thetase [22] and of cytosolic GSH S-transferase [23] 
activities, a 25% (w/v)  homogenate in 0.25 M su- 
crose/0.01 M Tris-HC1 buffer (pH 7.5) was made. In 
the case of y-glutamylcysteine synthetase the ho- 
mogenate was centrifuged at 10000 X g for 20 min 
at 4°C and in the case of GSH S-transferase the 
homogenate centrifuged at 700 X g for 10 min at 
4°C. In both cases the collected supernatant was 
centrifuged at 100000Xg for 60 min at 4°C to 
obtain the soluble fraction. 
For determinations of GSH peroxidase activity 
[24], liver was perfused with 0.154 M KC1 at 0°C. A 
20% (w/v)  homogenate in 0.154 M KC1 was made. 
After centrifugation at 1000 X g for 10 min at 4°C, 
the supernatant was collected and diluted with 3 
volumes of 0.154 M KC1. 
Liver slices were made using a Stadie and Riggs 
micrometer [25,26] and weighed in Krebs Improved 
Ringer II media. 
Blood was extracted by cardiac puncture and also 
from the portal vein and suprahepatic veins [27,28] 
from rats anesthesized with diethyl ether. Blood was 
rapidly mixed 1:1 (v/v)  or 2:1 (v/v)  with 13.6 mM 
DTNB in 0.1 M sodium phosphate-5 mM EDTA 
buffer (pH 7.5) at 0°C [29]. Blood plasma was ob- 
tained by centrifugation at 9000 X g for 1 min. This 
procedure did not originate detectable hemolysis 
measured by the cyanmethemoglobin method [30]. 
2.4. Enzyme actA, ities 
y-Glutamyl transferase activity was determined ac- 
cording to Szasz [31,32]. The specific activity was 
expressed as nmol of 3-carboxy-4-nitroanilide 
formed/min per mg protein, y-Glutamylcysteine syn- 
thetase activity was determined as described by Chung 
and Maines [22] and Sekura and Meister [33]. The 
specific activity was expressed as nmol of inorganic 
phosphate released per min per mg protein. Cytosolic 
GSH S-transferase activity was determined as de- 
scribed by Habig et al. [34] using CDNB as substrate. 
GSH peroxidase activity was measured according to 
Pinto and Bartley [24] using hydrogen peroxide and 
cumene hydroperoxide [35]. 
2.5. Determinations of total and non-protein thiols, 
cysteine and GSH 
Total and non-protein thiols were measured using 
Ellman's reagent [21]. Cysteine was measured ac- 
cording to Gaitonde [20]. Liver GSH was determined 
using GSH peroxidase and GSSG reductase. To ob- 
tain a GSH peroxidase xtract, rat livers were re- 
moved, chilled to 0°C and perfused using 0.154 M 
KC1. After they were minced, the tissue was ho- 
mogenised in 4 volumes of a solution 1:1 (v/v)  in 
0.154 M KC1 and 0.25 M potassium phosphate buffer 
(pH 7.4).The homogenate was centrifuged at 30000 
X g at 0°C for 20 min. The supernatant was collected 
and centrifuged again at 100000 x g at 0°C for 60 
min. One ml of the soluble fraction was put into 
small sterilised flasks and lyophilised for future use. 
To determine GSH the incubation media consisted of 
0.5 ml of the GSH peroxidase xtract diluted 1,/40 in 
equal parts of 0.154 M KC1 and 0.25 M potassium 
phosphate buffer pH 7.4, and 25 /~1 of 0.4 M sodium 
azide. Sodium azide was used in order to inhibit the 
catalase present in the extract. This mixture was 
allowed to stand for about 10 min. Afterwards 0.25 
ml of neutralised liver supernatant and 0.25 ml of 10 
mM hydrogen peroxide were added. After stirring, 
the system was incubated for 20 min at 30°C. Reac- 
tion was stopped with 0.25 ml of cold 10% (w/v)  
HPO 3. The precipitated proteins were removed by 
centrifugation at 30 000 X g for 20 rain at 4°C. GSSG 
formed was determined in the supernatant using 
GSSG reductase and NADPH according to Pinto and 
Bartley [24]. The apparent molar absorption coeffi- 
cient obtained for NADPH using hydrogen peroxide 
and cumene hydroperoxide was 6000 M-~ cm-J 
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Blood plasma total glutathione was determined 
using DTNB and GSSG reductase according to Ti- 
etze [36,37]. 
2.6. Incorporation of [35S]cysteine in GSH, in cys- 
teinylglycine and in y-glutamylcysteine catalysed by 
liver homogenates 
For these studies the incubation medium consisted 
of 1.5 ml of 10% (w/v)  liver homogenate in 0.05 M 
potassium phosphate buffer (pH 7.4). It was also 
added 2.9 rnM ATP, 11.4 mM MgC12, 0.2 mM 
[3SS]cysteine (0.67 GBq//xmol; 18 /xCi//xmol), 1 
mM glutamic acid and 1 mM glycine. The final 
volume was 1.75 ml. After incubation in a shaking 
bath at 30°C for 10, 20, 40 and 60 min, 0.5 ml of 
10% (w/v)  HPO 3 were added. After centrifugation at
9000 X g for 10 min, 15 /xl of 10 N NaOH and 0.2 
ml of 0.02 M DTNB were added to 0.75 ml of the 
supernatant for separation by HPLC. During 17 min, 
1 ml aliquots of the HPLC eluent were collected and 
0.9 ml of each aliquot was added to 10 ml of a 
solution consisting of 0.4% PPO and 0.02% POPOP 
in toluene/Triton X-100 (2:1, v /v)  [38]. Quantita- 
tion of radioactivity was made using a liquid scintilla- 
tion counter (Kontron BETAmatic). 
2.7. Uptake of [35S]cysteine into liver slices and 
incorporation in GSH, in cysteinylglycine and in 
y-glutamylcysteine 
A 25 ml flask containing 0.3 g of liver slices, 1.4 
ml of Krebs Improved Ringer II, 50 /.~1 of 5.8 mM 
[3SS]cysteine (0.8 GBq//zmol; 21.5 /zCi//xmol) and 
25 /zl glycine was incubated in a shaking bath at 
37°C. After 30 min the liquid was rapidly decanted to 
a centrifuge tube and centrifuged at 2000 X g for 10 
min. The liver slices were washed with 2 X 0.7 ml of 
0.154 M KC1, 1.95 ml of 3% (w/v)  HPO 3 were 
added and the slices were homogenised. The washing 
media and the homogenate were centrifuged at 2000 
X g for 10 min. To 0.75 ml of the three supernatants 
obtained, 25 /zl of NaOH 10 N and 0.1 ml of 0.03 M 
DTNB were added for subsequent separation in 
HPLC. During 17 min, 1 ml aliquots of the HPLC 
eluent were recovered and 0.9 ml of each aliquot was 
added to 10 ml of a solution consisting of 0.4% PPO 
and 0.02% POPOP in toluene/Triton X-100 (2:1, 
v /v)  [38] for liquid scintillation counting. 
2.8. Separation of liuer non-protein thiols by HPLC 
Separation of cysteine, y-glutamylcysteine, cys- 
teinylglycine and GSH was done by reversed-phase 
HPLC after reaction with DTNB by the method of 
Reeve et al. [39] modified for improved resolution. 
The modifications included the use of a 5 /~m 
Lichrospher 100 RP-18 (250 X 4 ram) reverse-phase 
column, a RP-8 precolumn (25 X 4 mm) (Merck, 
Darmstadt) and the use of 0.023 M ammonium for- 
mate (pH 5)/methanol (95:5, v /v )  as solvent with a 
flow rate of 1 ml/min. All separations were done in 
a LKB HPLC system. The samples were injected 
using a 20 /xl loop and thiols were detected at 280 
nm. Between each sample injection the column was 
eluted with methanol/water (30:70, v /v )  for about 
15 min. Under the experimental conditions used cys- 
teine was eluted at 6.4 min, y-glutamylcysteine at 8.6 
min, cysteinylglycine at 10.5 min and GSH 13.9 min. 
2.9. GSH degradation 
For these studies 1.5 ml of 10% (w/v)  liver 
homogenate and 0.05 M potassium phosphate buffer 
pH 7.4 to make a final volume of 1.75 ml were 
incubated for 10/min at 30°C. For some studies 2.9 
mM ATP was added. Reaction was stopped by the 
addition of cold 10% (w/v)  HPO 3. The precipitated 
proteins were removed by centrifugation at 30 000 X g 
for 10 min at 4°C. Cysteine was determined using the 
method of Gaitonde [20]. 
2.10. Protein determination 
For y-glutamyl transferase activity determinations, 
protein was determined using the biuret method [40]. 
For y-glutamylcysteine synthetase and GSH S-trans- 
ferase activity determinations, protein was deter- 
mined using the method of Peterson [41,42]. Bovine 
serum albumin was used as standard. 
2.11. Data statistical analysis 
Data statistical analysis was undertaken using the 
unpaired Student's t-test. 
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3. Results 
3.1. Endogenous thiol concentration in foetal- non- 
treated and DEN-treated rat liver 
Non-protein thiols concentration in DEN-treated 
rats was higher (P  < 0.001) than in non-treated rats 
(Table 1) but no differences were observed in total 
thiols and protein thiols (Table 1). This increase in 
non-protein thiols concentration was due to an in- 
crease in GSH concentration as for this compound an 
approximately equal increase was observed and no 
differences in cysteine concentration could be ob- 
served (Table 1). 
In foetal rat liver GSH and non-protein thiols 
concentrations were only 47% and 65% respectively 
of those found in young adult rat liver. The value 
obtained for GSH was about the same of that ob- 
tained by Pallardo et al. [43] for 22 days gestation 
foetal rat liver -3 .1  mM. 
GSH concentration i  rat liver increased with age 
(Table 1). GSH concentration in foetal liver was 
about 3 mM increasing to 7 mM in young adult liver 
and to 8 mM in liver of 8 months old rats. 
GSH concentration in rat liver was in general 
85 -95% of the concentration of non-protein thiols 
(Table I). and cysteine concentration had a value 
corresponding to the difference between GSH con- 
centration and non-protein thiols. Therefore soluble 
thiols other than GSH and cysteine have very small 
concentrations. Foetal rat liver was an exception since 
GSH concentration in it was only about 60% of 
non-protein thiols concentration. In this case cysteine 
concentration was not sufficiently high to explain the 
difference and so in foetal rat liver there were about 
40% non-protein thiols that were neither GSH nor 
cysteine. Using HPLC (see Section 2.6) it was found 
that neither cysteinylglycine nor y-glutamylcysteine 
were responsible for this difference in foetal rat liver 
(results not shown). It appears acceptable to suggest 
that in foetal liver possibly unknown thiols were 
present at a relatively high concentration. 
3.2. y-Glutamyl transferase activity 
y-Glutamyl transferase activity was increased about 
sevenfold (P<0.001)  in DEN-treated rats when 
compared with non-treated rats (Fig. 1). In foetal rat 
liver y-glutamyl transferase activity was similar to 
that in DEN-treated rats. Also y-glutamyl transferase 
activity in 8 months old rat liver was triple of that in 
young adult rat liver (Fig. 1). 
In DEN-treated rat liver y-glutamyl transferase 
was also obtained by measuring cysteine formation 
from GSH catalysed by homogenates (Fig. 2). Rate 
of cysteine formation from GSH in the absence of 
ATP can be considered an estimate of y-glutamyl 
transferase activity, as cysteine is essentially formed 
Table 1 
GSH, non-protein-thiols, cysteine and total thiols endogenous concentrations in non-treated-, DEN-treated-, foetal- and young adult rat 
liver 
Rat liver Concentration (/~mol/g fresh liver) 
GSH Non-protein thiols Cysteine Total thiols 
Non-treated 8.09 ± 0.41 8.85 _+ 0.61 0.13 _+ 0.04 25.69 ± 1.30 
DEN-treated 9.48 ± 0.63 a 10.68 _+ 0.99 a 0.16 ± 0.02 26.79 ± 1.80 
Foetal 3.42 _+ 0.13 h 5.60 ± 0.43 b 0.17 ± 0.02 16.23 ± 0.82 b 
Young adult 7.29 ± 0.44 8.61 ± 0.68 0.17 ± 0.03 27.40 ± 1.37 
In all determinations liver was immediately placed in liquid nitrogen and afterwards pulverized. For GSH and cysteine determinations 
25% (w/v) homogenates in 3% (w/v) metaphosphoric a id and 5% (w/v) perchloric acid were made respectively. For total thiols 
determinations liver was homogenized in 39 volumes of 0.154 M potassium chloride. For non-protein thiols determinations 0.2 g of 
pulverized liver were added to a mixture of 1.0 ml of 0.154 M potassium chloride and 0.5 ml of 10% (w/v) metaphosphoric a id. For 
further experimental details see Section 2. Data represent mean ± S.D. of at least 6 animals except in the case of foetal iver where a pool 
of animals was used. Foetal rat liver = liver from foetus with 18 days gestation. Young adult rats = 3 months old rats. Non-treated and 
DEN-treated rats were 8 months old. Statistical significant differences are indicated. 
P < 0.001 when compared with non-treated rats; 
b p < 0.001 when compared with young adult rats 
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Fig. 1. Specific activity of y-glutamyl transferase in foetal, young 
adult, non-treated and DEN-treated rat liver. Activity is in nmol 
p-nitroanil ide/min/mg protein. Data represent the mean + SD of 
at least six experiments. 
from GSH through catalysis by y-glutamyl trans- 
ferase followed by cysteinylglicinase and/or amino- 
peptidase M catalysed hydrolysis of cysteinylglycine. 
It can be considered that cysteiny!glycinase and/or 
aminopeptidase M activity is not rate limiting since 
cysteinylglycine concentration i liver is very low 
(29,6 _+ 10 /zM according to [44]). When enough 
ATP is present cysteine can be used for GSH synthe- 
sis through the reactions catalysed by the ATP depen- 
dent enzymes y-glutamylcysteine synthetase and GSH 
synthetase. Rate of cysteine formation by DEN-treated 
rats was about nine times higher than in non-treated 
rats (Fig. 2). In the presence of added ATP, as 
expected, rate of cysteine formation from GSH was 
decreased about 60%. 
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Fig. 2. Formation of cysteine from GSH catalysed by ho- 
mogenates of non-treated and DEN-treated rat liver. Cysteine was 
determined according to Gaitonde [20]. [ATP] = 2.9 mM. Data 
represent the mean _+ S.D. of at least four experiments. Light area 
= non-treated rats; dark area = DEN-treated rats. 
3.3. Determination GSH blood plasma concentration 
and of sinusoidal GSH efflux 
GSH blood plasma concentration was increased 
(P  < 0.001) in DEN-treated rats when compared to 
non-treated rats (Table 2). GSH concentration ob- 
tained for non-treated rats was in agreement with the 
values found in the literature for adult rats which are 
in the range 10-21 /xM [29,44-46]. 
GSH sinusoidal efflux was determined through 
measurements of arteriovenous gradient of GSH blood 
plasma concentration. The concentrations of blood 
plasma GSH in portal vein and in suprahepatic veins 
were different for non-treated and DEN-treated rats 
(Table 2). However the difference in GSH concentra- 
tion between the portal vein and suprahepatic veins 
was 11.6 ___ 3.6 /zM for non-treated rats and 11.3 + 
3.8 /zM for DEN-treated rats. These values were in 
agreement with the results of Lauterburg et al. [29] 
for the arteriovenous gradient of GSH plasma con- 
centration in rats. 
3.4. GSH S-transferase and GSH peroxidase activity 
Cytosolic GSH S-transferase activity towards 
CDNB was increased twofold in DEN-treated rats 
when compared to non-treated rats (Table 3). 
GSH peroxidase total activity was decreased (P < 
0.01) in DEN-treated rats when compared to non- 
Table 2 
Total GSH (GSH + GSSG) concentration (in GSH equivalents) in
blood plasma of non-treated and DEN-treated rats 
GSH (/zM) 
Cardiac Portal vein a Suprahepatic 
Puncture veins 
Non-treated 12.7_+1.6 11.0_+2.2 b 22.6_+2.8 
DEN-treated 17.4_+2.1 c 18.9_+5.1 ~e 31.1 _+3.9 d 
Extracted blood was rapidly mixed 1:1 (v /v )  or 2:1 (v /v )  with 
13.6 mM DTNB in 0.1 M sodium phosphate-5 mM EDTA buffer 
(pH 7.5) at 0°C and blood plasma was obtained by centrifugation 
at 9000 × g for 1 min. Data represent the mean + S.D. of at least 
7 animals. Statistical significant differences are indicated. 
a According to Lauterburg et al. (1984) arterial GSH concentra- 
tion is identical to the concentration i the portal vein. 
b p < 0.001 and e p < 0.002 when compared with suprahepatic 
veins. 
c P < 0.001 and d p < 0.01 when compared with non-treated 
rats. 
H.S. Marinho et al. / Biochimica et Biophysica Acta 1360 (1997) 157-168 163 
Table 3 
Cytosolic GSH S-transferase and GSH peroxidase activities in 
non-treated and DEN-treated rat liver 
Enzyme activity Non-treated DEN-treated 
GSH S-transferase a 1.6 4- 0.3 3.6 --}- 0.8 b 
Total GSH peroxidases c 1054 _ 98 787 _+ 120 d 
Selenium dependent 918 +87 661 + 120 ~ 
GSH peroxidase c 
GSH peroxidase 142 +49 131 +66 
(GSH S-transferase) c. 
Total GSH peroxidase activity was determined using cumene 
hydroperoxide as substrate and selenium dependent GSH peroxi- 
dase activity was determined using hydrogen peroxide as sub- 
strate. GSH peroxidase activity due to GSH S-transferase was 
obtained by the difference between the two determinations. Data 
represent the mean+S.D, of at least 10 animals. 
a/zmol GSH conjugated/min per mg protein; c nmol GSSG 
formed/min /mg protein. GSH S-transferase activity was deter- 
mined with CDNB as substrate. Statistical significant differences 
are indicated. 
b p < 0.001 and d p < 0.01 when compared with non-treated 
rats. 
treated rats (Table 3). This decrease was due to a 
decrease in selenium dependent GSH peroxidase ac- 
tivity for no differences were found in GSH peroxi- 
dase activity due to GSH S-transferase. 
3.5. GSH biosynthesis 
y-glutamylcysteine synthetase activity was in- 
creased twofold in DEN-treated rats (Fig. 3). Also 
y-glutamylcysteine synthetase activity increased with 
30 
~~ 
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~.----. 
~5 
o I 
Foetal Young adult Non-treated DEN-treated 
Fig. 3. Specific activity of y-glutamylcysteine synthetase in 
foetal, young adult, non-treated and DEN treated rat liver. Data 
represent the mean_+ SD of at least six experiments. 
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Fig. 4. y-glutamylcysteine synthetase activity as a function of 
GSH concentration i the reaction medium. Without added GSH, 
endogenous GSH concentration was 0.16 mM for non-treated rats 
and 0.19 mM for DEN-treated rats. The change in y-glutamylcy- 
steine synthetase activity was calculated in relation to the activity 
in the absence of exogenous GSH. Shaded area = non-treated 
rats; light area = DEN-treated rats. 
age. In young adult rat liver y-glutamylcysteine syn- 
thetase specific activity was increased 2.5 times com- 
pared to foetal rat liver and in 8 months old animals 
the activity was twice the one observed in young 
adult rat liver. 
y-glutamylcysteine synthetase activity is regulated 
by feedback inhibition by GSH [47] and so we stud- 
ied the effect of increasing GSH concentration i  the 
activity of the enzyme. Comparing the activities of 
y-glutamylcysteine synthetase in the presence of 5 
mM GSH and 0.19 mM GSH the increase in GSH 
concentration decreased y-glutamylcysteine syn- 
thetase activity about 30% (Fig. 4) both for non- 
treated and for DEN-treated rats. For GSH concentra- 
tions lower than 1 mM there was an inhibition of 
y-glutamylcysteine synthetase activity in non-treated 
rats but no differences were found in DEN-treated 
rats. Inhibition of y-glutamylcysteine synthetase 
caused by 1 mM GSH is identical to the one caused 
by 5 mM GSH for non-treated and DEN-treated rats. 
So it can be concluded that no significant differences 
were found in y-glutamylcysteine synthetase feed- 
back inhibition by GSH for GSH concentrations closer 
to the endogenous value in rat liver. 
GSH, y-glutamylcysteine and cysteinylglycine 
synthesis from cysteine was studied using [35S]cy- 
steine. Initial rate of y-glutamylcysteine formation in 
DEN-treated rats was 50-100% higher than in non- 
treated rats (Fig. 5). This increase was in agreement 
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Fig. 5. Formauon of y-glutamylcysteine, cysteinylglycine and 
GSH in liver homogenates of non-treated and DEN-treated rats as 
a function of incubation time with [35S]cysteine. (0,  O), -y- 
glutamylcysteine; ( l  I ,  []), cysteinylglycine; (z~, • )  GSH. All 
three thiols were separated by HPLC. Data represent the mean + 
SD of at least four experiments. Open symbols, non-treated rats; 
full symbols, DEN-treated rats. 
with the higher y-glutamylcysteine synthetase activity 
found in DEN-treated rats (Fig. 3). y-glutamylcy- 
steine concentration i creased and reached a maxi- 
mum value beyond which the rate of y-glutamylcy- 
steine disappearance was about the same for non- 
treated and DEN-treated animals. 
In DEN-treated rats GSH formation from [35S]cy- 
steine after 10 min was about twofold that in non- 
treated rats (Fig. 5). However for longer incubation 
times while in non-treated rats there was an almost 
linear accumulation of GSH, for DEN-treated rats 
there was a decrease in GSH concentration. This was 
in agreement with the fact that the rate of GSH 
formation from y-glutamylcysteine was similar for 
both types of rats (Fig. 5). The difference in GSH 
concentration bserved in Fig. 5 was probably due to 
the higher activity of y-glutamyl transferase which 
caused a higher degradation of GSH in DEN-treated 
rats. As this higher GSH degradation did not form 
higher levels of cysteinylglycine (Fig. 5) it is proba- 
ble that cysteinylglycinase and/or aminopeptidase M 
activities were increased in DEN-treated rats. 
3.6. Cysteine uptake into liver slices 
[35S]cysteine and also [3sS]GSH concentration i
DEN-treated rat liver slices after 30 rain was higher 
(P  < 0.002 and P < 0.05, respectively) than in non- 
treated rats. This indicates that the rate of cysteine 
transport into liver cells was higher in DEN-treated 
rats. [35S]cysteinylglycine and [35S]-y-glutamylcy- 
steine were not detected. 
4. Discussion 
Hepatic GSH steady-state concentration is achieved 
by a balance between its formation and disappearance 
(utilisation and/or export). So, hepatic GSH steady- 
state concentration is dependent on the rate of synthe- 
sis catalysed by y-glutamylcysteine synthetase and 
GSH synthetase or formation through GSSG reduc- 
tase, on the rate of utilisation through redox reactions 
catalysed by GSH peroxidases, and conjugation reac- 
tions catalysed by GSH S-transferase, and on the rate 
of GSH effiux from the liver [48]. 
The increase in GSH endogenous concentration 
observed in DEN-treated rat liver (Table 1) was in 
agreement with the observations made by other au- 
thors during hepatocarcinogenesis [13-16]. GSH in- 
creased concentration was accompanied by an in- 
crease in y-glutamyl transferase activity (Fig. 1) 
which was in agreement with the role proposed for 
y-glutamyl transferase in the uptake of aminoacids 
needed for intracellular GSH synthesis [17]. Both 
y-glutamylcysteine synthetase (Fig. 3) and cytosolic 
GSH S-transferase (Table 3) activities were also 
increased. In foetal rat liver y-glutamyl transferase 
activity was about the same as that found in DEN- 
treated rat liver (Fig. 1). However GSH concentration 
(Table 1) and y-glutamylcysteine synthetase activity 
were very low which is in contrast to DEN-treated rat 
liver where y-glutamylcysteine synthetase activity 
was increased compared to non-treated rat liver (Fig. 
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3). In fact, we found a exponential dependence of 
liver GSH concentration on y-glutamylcysteine syn- 
thetase activity (Fig. 7). So, it is probable that ,/- 
glutamylcysteine synthetase, is a key factor in the 
increase of endogenous GSH concentration, since this 
enzyme is the rate-limiting enzyme for GSH synthe- 
sis. 
The increased activity 3,-glutamylcysteine syn- 
thetase in DEN-treated rats does not seem to be due 
to an altered feedback inhibition by GSH (Fig. 4). It 
could be due to an increased enzyme synthesis asso- 
ciated to an increase in GSH S-conjugate concentra- 
tion which can diminish y-glutamylcysteine syn- 
thetase feedback inhibition by GSH [49]. In DEN- 
treated rat liver cytosolic GSH S-transferase activity 
was increased (Table 3) probably due to detoxifica- 
tion of DEN [50] producing a higher GSH S-con- 
jugates concentration which may be partially respon- 
sible for the increased 7-glutamylcysteine synthetase 
activity, So the toxic exposure to DEN results in a 
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higher utilisation of this compound for conjugation 
reactions and in a greater requirement for synthesis to 
maintain adequate liver GSH concentrations. The in- 
creased activity of 7-glutamylcysteine synthetase 
would be futile without an increased rate of cysteine 
formation which is rate-limiting for GSH synthesis. 
The fact that there was an increase of cysteine uptake 
in DEN-treated rat liver (Figs. 6 and 7) was in 
agreement with a higher requirement of cysteine for 
GSH synthesis. 
The liver is the major source of blood plasma GSH 
[29]. Liver GSH is released mainly into blood plasma 
[51], while GSSG and GSH S-conjugates are released 
into the bile [52,53]. Blood plasma GSH concentra- 
tion is probably a function of an interorgan homeo- 
static equilibrium where the liver has an important 
function as the main supplier of GSH to be used by 
other organs [47,54]. Blood plasma GSH was in- 
creased about 40% in DEN-treated rats (Table 2) 
which suggested an increased GSH liver sinusoidal 
efflux. However no differences were found in hepatic 
arteriovenous GSH concentration gradient (Table 2) 
for non-treated and DEN-treated animals. 
Intact GSH does not enter into hepatocytes [55], 
and so there are indirect ways for GSH to be trans- 
ported into hepatocytes, involving ,/-glutamyl trans- 
ferase. 7-glutamyl transferase localisation in rat liver 
plasma membrane was initially considered to be 
canalicular [56,57] being absent from the sinusoidal 
membrane [58]. However recent studies showed the 
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presence of 7-glutamyl transferase in the sinusoidal 
membrane [59-61] with one study even suggesting 
that enzyme localisation is mainly sinusoidal [62]. So, 
when liver 7-glutamyl transferase activity is low, 
most of the GSH exported from the liver can not be 
recovered by this organ (indirectly and mainly as 
cysteine) through intrahepatic circulation. In fact nor- 
mal rat liver is capable of intrahepatic degradation of 
only 20-25% of GSH exported to blood plasma [63]. 
However when y-glutamyl transferase activity is high, 
most of GSH effluxed from the liver can be recov- 
ered. In guinea-pig liver y-glutamyl transferase activ- 
ity is about sevenfold higher than in rat liver [64] and 
so comparable to that observed in DEN-treated liver 
(Fig. 1). So guinea pig liver can be considered a
possible physiological model for comparative studies 
with hepatomized liver regarding GSH efflux and 
recovery by intrahepatic circulation. Guinea pig liver 
perfusion, showed that in a single pass 50-90% of 
the GSH (10-50/zM) added to the caval perfusate is
removed by the liver [64]. Removal of portal GSH is 
dependent on 7-glutamyl transferase activity for inhi- 
bition of 7-glutamyl transferase increased three to six 
times the apparent GSH efflux [64]. So although no 
differences were found in hepatic arteriovenous GSH 
concentration gradient (Table 2) for DEN-treated and 
non-treated animals, the fact that 7-glutamyl trans- 
ferase activity was increased sevenfold in DEN- 
treated rats (Fig. 1 and Fig. 2) suggests that in 
DEN-treated rats there was an increased GSH sinu- 
soidal efflux. 
GSH canalicular efflux increases linearly with GSH 
concentration i crease in rat liver [65]. As the rate of 
GSH efflux is given by the equation z =4.4 x 
10-4[GSH] the rate of GSH canalicular efflux should 
be 3.56 nmol GSH/min /g  liver for non-treated rats 
and 4.17 nmol GSH/min per g liver for DEN-treated 
rats. Just like it happens with GSH effluxed to plasma, 
part of GSH effluxed canalicularly can be hydrolysed 
by y-glutamyl transferase and dipeptidase forming 
glutamate, glycine and cysteine [66] and possibly 
recovered by the liver through the intrahepatic circu- 
lation of these aminoacids [67] that can be used to the 
intracellular synthesis of GSH. 
So, in DEN-treated liver the increased activity of 
7-glutamyl transferase can be considered a compen- 
satory mechanism for the increased GSH sinusoidal 
and canalicular efflux allowing recovery by the liver 
of the aminoacids needed to synthesise GSH. The 
reason for this increased GSH efflux is not clear. 
However in other pathological conditions, namely 
ethanol ingestion [68] and carbon tetrachloride liver 
damage [69] GSH sinusoidal efflux is also increased. 
This suggests that increased GSH efflux could be 
linked to detoxification. 
Finally it should be noted that enzyme activities 
involved in GSH biosynthesis and degradation during 
DEN carcinogenesis are increased, and so y-glutamyl 
cycle must function at a higher ate than in non-treated 
rat liver. Also GSH effiux and indirect influx (via 
y-glutamyl transferase) are increased. GSSG reduc- 
tase activity is also increased [11]. So GSH 
metabolism is faster with the exception of oxidation 
processes as shown by the lower GSH peroxidase 
activities (Table 3). Therefore during carcinogenesis 
GSH metabolism is faster and has a tendency to be 
reductive. As GSH synthesis is dependent on ATP, 
this increased rate of y-glutamyl cycle is probably a 
futile waste of energy leading to mitochondria deteri- 
oration. In fact, in neoplastic ells there is a decrease 
in the number of mitochondria [70] and of ATP 
concentration [71]. So the decreased GSH concentra- 
tion found in hepatomas could be due to lack of ATP 
necessary for GSH biosynthesis. 
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